Theranexus
Theranexus is an innovative biopharmaceutical company originating from the CEA, specializing in the treatment of rare neurological diseases. It has a unique platform for identifying and characterizing advanced therapy drug candidates and has a lead drug candidate in clinical development for Batten disease. The company is listed on Euronext Growth in Paris and aims to develop therapies for neurological disorders.
Industries
Nr. of Employees
small (1-50)
Products
Drug candidate for Batten disease (CLN3)
Clinical-stage therapeutic candidate developed for the juvenile form of Batten disease (CLN3); evaluated in Phase 1/2 studies with longitudinal biomarker (neurofilament) assessment and real‑world data reporting.
Wake‑promoting drug candidate for sleep disorders and Parkinson’s-related daytime sleepiness
Clinical-stage candidate developed to treat excessive daytime sleepiness and related sleep disorders; progressed through Phase 1 and Phase 2 studies with regulatory interactions.
Cognitive disorder drug candidate for neurocognitive symptoms (Alzheimer’s disease)
Candidate evaluated in early clinical studies (Phase 1b) for neurocognitive disorders and presented at clinical conferences.
Antisense oligonucleotide candidate for lysosomal/TFEB-related indications
Oligonucleotide program developed via collaborations and funded projects to target lysosomal pathways relevant to rare neurological diseases.
Drug candidate for Batten disease (CLN3)
Clinical-stage therapeutic candidate developed for the juvenile form of Batten disease (CLN3); evaluated in Phase 1/2 studies with longitudinal biomarker (neurofilament) assessment and real‑world data reporting.
Wake‑promoting drug candidate for sleep disorders and Parkinson’s-related daytime sleepiness
Clinical-stage candidate developed to treat excessive daytime sleepiness and related sleep disorders; progressed through Phase 1 and Phase 2 studies with regulatory interactions.
Cognitive disorder drug candidate for neurocognitive symptoms (Alzheimer’s disease)
Candidate evaluated in early clinical studies (Phase 1b) for neurocognitive disorders and presented at clinical conferences.
Antisense oligonucleotide candidate for lysosomal/TFEB-related indications
Oligonucleotide program developed via collaborations and funded projects to target lysosomal pathways relevant to rare neurological diseases.
Services
Joint research projects and public–private laboratories to co-develop discovery programs, imaging studies, and AI/ML tools for neurological disease targets.
Out‑licensing and commercialization agreements to enable market development and distribution of clinical-stage candidates.
Provision of platform-based screening to identify modulators of neuron–glia biology for early-stage therapeutic discovery.
Joint research projects and public–private laboratories to co-develop discovery programs, imaging studies, and AI/ML tools for neurological disease targets.
Out‑licensing and commercialization agreements to enable market development and distribution of clinical-stage candidates.
Provision of platform-based screening to identify modulators of neuron–glia biology for early-stage therapeutic discovery.
Expertise Areas
- Drug discovery for rare neurological disorders
- Neuron–glia interaction screening
- Antisense oligonucleotide therapeutics
- Clinical trial management in neurology
Key Technologies
- High-throughput screening of neuron–glia interactions
- AI / machine learning for target identification
- Neuroimaging for translational drug development
- Antisense oligonucleotide design
News & Updates
Details about the upcoming general assembly meeting scheduled for June 26, 2025.
Details about the general assembly meeting held on June 27, 2024, including voting results.
Details about the general assembly meeting held on June 8, 2023, including voting results and reports.
Details about the general assembly meeting held on June 22, 2022, including voting results and reports.
The company announced its financial results for 2024 and provided updates on its ongoing projects.
Theranexus and BBDF announced positive real-world data supporting the efficacy of Batten-1 in treating Batten disease.
Details about the upcoming general assembly meeting scheduled for June 26, 2025.
Details about the general assembly meeting held on June 27, 2024, including voting results.
Details about the general assembly meeting held on June 8, 2023, including voting results and reports.
Details about the general assembly meeting held on June 22, 2022, including voting results and reports.
The company announced its financial results for 2024 and provided updates on its ongoing projects.
Theranexus and BBDF announced positive real-world data supporting the efficacy of Batten-1 in treating Batten disease.